Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Mina Boazak, Benjamin Kahn, Lindsay Cox, James Ragazino, David R Goldsmith, Robert O Cotes
{"title":"Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.","authors":"Mina Boazak, Benjamin Kahn, Lindsay Cox, James Ragazino, David R Goldsmith, Robert O Cotes","doi":"10.3371/CSRP.BOKA.061518","DOIUrl":null,"url":null,"abstract":"<p><p>Clozapine-induced neutropenia occurs in 3-5% of individuals treated with clozapine. Current US guidelines require interruption of clozapine when the absolute neutrophil count (ANC) drops below 1000 cells/mm<sup>3</sup>. There is minimal available guidance for what dosing schedule to use when restarting clozapine after an episode of neutropenia. Here, we present a case of a 50-year-old Caucasian female with a history of schizoaffective disorder who was successfully rechallenged on clozapine one month after developing clozapine-induced neutropenia (ANC 600 cells/mm<sup>3</sup>). To understand published re-titration rates of clozapine after neutropenia, we conducted a literature review using a using the PubMed database and found only seven case reports that unambiguously reported a clozapine dosing schedule during re-challenge. All were successful except one, a case of clozapine rechallenge after agranulocytosis. Including this case presentation, six out of eight cases restarted clozapine more cautiously than recommended by the US guidelines for a new clozapine initiation. We cannot comment what role a slower or more rapid titration plays in a successful rechallenge after neutropenia with the available evidence. We encourage researchers to publish their dosing schedule in detail after an episode of neutropenia or agranulocytosis.</p>","PeriodicalId":40019,"journal":{"name":"Clinical Schizophrenia and Related Psychoses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443488/pdf/nihms-1019026.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Schizophrenia and Related Psychoses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3371/CSRP.BOKA.061518","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Clozapine-induced neutropenia occurs in 3-5% of individuals treated with clozapine. Current US guidelines require interruption of clozapine when the absolute neutrophil count (ANC) drops below 1000 cells/mm3. There is minimal available guidance for what dosing schedule to use when restarting clozapine after an episode of neutropenia. Here, we present a case of a 50-year-old Caucasian female with a history of schizoaffective disorder who was successfully rechallenged on clozapine one month after developing clozapine-induced neutropenia (ANC 600 cells/mm3). To understand published re-titration rates of clozapine after neutropenia, we conducted a literature review using a using the PubMed database and found only seven case reports that unambiguously reported a clozapine dosing schedule during re-challenge. All were successful except one, a case of clozapine rechallenge after agranulocytosis. Including this case presentation, six out of eight cases restarted clozapine more cautiously than recommended by the US guidelines for a new clozapine initiation. We cannot comment what role a slower or more rapid titration plays in a successful rechallenge after neutropenia with the available evidence. We encourage researchers to publish their dosing schedule in detail after an episode of neutropenia or agranulocytosis.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氯氮平诱发中性粒细胞减少症或粒细胞减少症后的再用药率:病例报告和文献综述。
在接受氯氮平治疗的患者中,3%-5% 会出现氯氮平诱发的中性粒细胞减少症。美国现行指南要求,当绝对中性粒细胞计数(ANC)低于 1000 cells/mm3 时,应中断氯氮平治疗。关于中性粒细胞减少症发作后重新开始氯氮平治疗时应采用何种给药方案,目前只有极少的指导意见。在此,我们介绍了一例 50 岁的白种女性病例,她有精神分裂症病史,在出现氯氮平引起的中性粒细胞减少症(ANC 600 cells/mm3)一个月后,她成功地重新服用了氯氮平。为了了解已发表的中性粒细胞减少症患者重新服用氯氮平的比率,我们使用 PubMed 数据库进行了文献综述,结果发现只有七篇病例报告明确报道了重新挑战期间氯氮平的给药时间表。除了一例在粒细胞减少后再次使用氯氮平的病例外,其他病例均获得成功。包括这个病例在内,8 个病例中有 6 个病例在重新开始使用氯氮平时比美国氯氮平新药指南所建议的更加谨慎。根据现有证据,我们无法对中性粒细胞减少症后滴定更慢或更快对成功重新用药所起的作用发表评论。我们鼓励研究人员在发生中性粒细胞减少或粒细胞减少后详细公布其用药计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Schizophrenia and Related Psychoses
Clinical Schizophrenia and Related Psychoses Medicine-Psychiatry and Mental Health
自引率
0.00%
发文量
0
期刊介绍: The vision of the exciting new peer-reviewed quarterly publication Clinical Schizophrenia & Related Psychoses (CS) is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. CS is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.
期刊最新文献
Dysexecutive Behavior in First-Episode Schizophrenia. Dysexecutive Behavior in First-Episode Schizophrenia Grading meningiomas by used imaging features on magnetic resonance imaging The Association between Serum Levels of Ferritin and D-Dimer with Liver Function Tests in Patients with COVID-19 Role of Susceptibility Weighted Magnetic Resonance Imaging in Neurological Diagnosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1